nivolumab

Details

Files

Generic Name:

nivolumab

Project Status:

Pending

Therapeutic Area:

Hodgkin lymphoma

Manufacturer:

N/A

Call for patient/clinician input open:

November 21, 2024

Brand Name:

N/A

Project Line:

Reimbursement Review

Project Number:

PX0376-000

Call for patient/clinician input closed:

January 17, 2025

Biosimilar:

Submission Type:

Non-sponsored Submission

Fee Schedule:

Pending

Indications:

With doxorubicin, vinblastine and dacarbazine (AVD) in previously untreated stage III or IV Hodgkin Lymphoma.

Anticipated Date:

November 12, 2024

Last Updated : November 21, 2024